Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)
2026-05-31 06:11:04 ET
Initiating Alcon with a buy rating
I initiate coverage of Alcon Inc. ( ALC ) with a “Buy rating.” My buy rating is based on a view that the market has potentially overpenalized the company for a near-term headwind or uncertainty on a) softness in cataract revenue stream, b) international implantable pressure, c) China related procurement risks, and c) tariff-driven margin headwind, however, I see that the market may be underappreciating the company’s 2026–2027 product cycle (breath-related). In my view, Alcon is entering an era where the multiple growth drivers are improving, for example, the unity surgical equipment replacement, consumables pull-through, PanOptix Pro premium IOL stabilization, Precision7 contact lens share gains, and the launch of Tryptyr as a novel branded dry-eye product....
Read the full article on Seeking Alpha
For further details see:
Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)
NASDAQ: ALC
ALC Trading
1.47% G/L:
$66.75 Last:
666,267 Volume:
$66.93 Open:
